Ro launched its GLP-1 Supply Tracker that will notify patients when a GLP-1 drug is back in the market, including the location of the pharmacies where it would be available.
The U.S. Food and Drug Administration (FDA) issued a limited supply notice for Wegovy, Zepbound, and Mounjaro due to its popular demand for patients.
Read Also : California Lawmakers Advance Proposals for AI Regulation Amid Increasing Deepfake Issues
GLP-1 Supply Trackers Alert Patients for Medication Availability
These days patients are having a hard time filling their prescriptions due to the limited supply of GLP-1 drugs. These drugs are known for being popular for patients with diabetes and those who push for weight loss.
"The GLP-1 shortage challenges are exacerbated by a lack of accurate, up-to-date, and accessible GLP-1 supply information. Patients deserve better," said Ro co-founder and CEO Zachariah Reitano.
The GLP-1 Supply Tracker relies on data from Ro's nationwide supply and user-generated reports. The company also gets the latest updates from the FDA to create real-time alerts for patients.
How GLP-1 Supply Tracker Works
The GLP-1 Supply Tracker will allow patients to sign up and be authorized to receive alerts once their medication is available. Patients will receive vital information like what drug is available and where it is available.
Moreover, the tracker will also give patients the chance to report important details. Users can create reviews specifying the drug, dose, and pharmacy where they got or failed to get stock. The data collected from patients will be added to the pool of sources of the company.
Eli Lilly, the maker of Zepbound and Mounjaro, is also creating the same tool. The company shared that they are currently working to update the supply website with heat maps to assist patients where they can buy their medications within the area.
